Cognizant to develop clinical trial platform for TransCelerate

Cognizant to develop clinical trial platform for TransCelerate

BureauUpdated: Saturday, June 01, 2019, 10:16 AM IST
article-image

New Delhi: IT firm Cognizant today said it will develop a subscription-based platform for TransCelerate BioPharma to help pharma companies collaborate for clinical trials and accelerate development of new medicines.

TransCelerate is a non-profit organisation representing 19 major pharma companies.

The ‘Shared Investigator Platform’ will enable the pharma industry to bring standardisation and consistency to clinical trials, Cognizant said in a statement.

Pharm firms often deploy investigator platforms individually resulting in clinical sites using multiple environments, introducing complexity and risk.

By bringing together clinical sites and sponsors spread across the world on a common platform, they can run clinical trials more efficiently and accelerate the development of new medicines, it said.

The new platform will enhance organisational productivity by providing investigators and site staff with a central, single access point to clinical trial information, enhancing accuracy and reducing study start-up time.

It will also help pharma firms improve quality, regulatory compliance, process visibility and capacity, while reducing investigator efforts related to training, document exchange and support.

In the future, the platform may provide regulators with an efficient electronic audit process and better insight into clinical trials.

“This collaboration is an important part of TransCelerate’s strategy to improve clinical trial processes in order to bring innovative new medicines to patients faster,” said Jackie Kent, Eli Lilly & Co Clinical Development Information and Optimisation Senior Director and TransCelerate Shared Investigator Platform Leader.

RECENT STORIES

Prime Minister Narendra Modi Says "Right Time" For Global Investors To Bet On The Indian Shipping...

Prime Minister Narendra Modi Says

United Breweries Reports 65% Decline In Net Profit To ₹46.34 Crore Due To Unusual Monsoon

United Breweries Reports 65% Decline In Net Profit To ₹46.34 Crore Due To Unusual Monsoon

Infrastructure Major Larsen & Toubro Reports 15.6% Increase In Net Profit To ₹3,926.09 Crore

Infrastructure Major Larsen & Toubro Reports 15.6% Increase In Net Profit To ₹3,926.09 Crore

Travel Tech Platform Ixigo Reports ₹3.46 Crore Loss In The September Quarter

Travel Tech Platform Ixigo Reports ₹3.46 Crore Loss In The September Quarter

Market Outlook: Technical Call Of The Day & Top 5 Stocks In Focus For October 30, 2025

Market Outlook: Technical Call Of The Day & Top 5 Stocks In Focus For October 30, 2025